We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.50 | 1.71% | 327.50 | 326.50 | 327.50 | 328.00 | 318.50 | 319.00 | 106,169 | 15:09:43 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -7.01 | 316.78M |
From May 2019 to May 2024
TIDMOXB
RNS Number : 2090V
Oxford Biomedica PLC
06 August 2015
Oxford BioMedica: Notice of Interim Results
Results date: 27 August 2015
Oxford, UK - 6 August 2015: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Group") a leading gene and cell therapy group, will be announcing its interim results for the six month months ended 30 June 2014 on Thursday 27 August 2015 at 7am BST.
An analyst briefing will be held at 9:30am BST on 27 August 2015 at the offices of Consilium Strategic Communications: 41 Lothbury, EC2R 7HG. An audio replay will be made available shortly after the presentation on the Group's website: www.oxfordbiomedica.co.uk.
-Ends-
For further information, please contact: Oxford BioMedica plc: Tel: +44 (0)1865 John Dawson, Chief Executive Officer 783 000 Tim Watts, Chief Financial Officer Media Enquiries: Tel: +44 (0)20 Mary-Jane Elliott/ Matthew Neal/ 3709 5700 Chris Welsh/ Laura Thornton Consilium Strategic Communications
Notes to editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector(R) IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk .
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLELFBEVFZBBV
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
